



### Dementia – so often misunderstood

11am GMT 25<sup>th</sup> February 2019



@ClubVita #dementia



linkedin.com/company/club-vita

### Introducing today's panel



**Dr James Pickett** 

Head of Research, Alzheimer's Society



**Prof Seth Love** 

Professor of
Neuropathology,
University of Bristol



**Dr Nick Cartmell** 

NHS General Practitioner; Primary Care Dementia Research Advisor, National Institute for Health Research



**Erik Pickett (Chair)** 

Longevity risk consultant
Club Vita



Join the discussion...

LinkedIn: Friends of Club Vita group; company/club-vita

Twitter: @ClubVita #dementia




# Dementia – so often misunderstood

James Pickett
Head of
Research
Alzheimer's
Society



**INFOGRAPHIC** 

### The global impact of dementia



rising to 63% in 2030

and 68% in 2050.



The total estimated worldwide cost of dementia in 2015 is US\$ 818 billion.

By 2018, dementia will become a trillion dollar disease, rising to

US\$ 2 trillion by 2030

If global dementia care were a country, it would be the

### 18th largest economy

in the world exceeding the market values of companies such as Apple and Google

people living

with dementia

in each world

region in 2015.

Apple \$742 billion Google \$368 billion (source: Forbes 2015 ranking)





We must now involve more countries and regions in the global action on dementia.


### Dementia v Alzheimer's














## Brain diseases cause dementia



Amyloid plaques
Form around brain
cells in Alzheimer's




Tau tangles
Alzheimer's and other
forms of dementia



Lewy bodies

Dementia with Lewy bodies, Parkinson's




Immune system (microglia)
Activated by protein aggregates

**Alzheimer's Society** 

### **Current state** of play

- Of the top ten causes of death it's the only one that we don't have effective ways to try and prevent, treat or cure the disease.
- Current treatments don't stop dementia progressing
- No treatments for 300,000 people in the UK
- A third of people living with dementia do not have a diagnosis
- No standardised care pathway for dementia






# Dementia in the UK: scale, costs and research



- Dementia costs: 2x cancer, 3x heart disease, 4x stroke
- 7x greater investment in cancer than dementia research



# A ticking time bomb or reason for hope?



### **About us**



- UK's leading dementia charity
- United against dementia for 40 years
- The only UK charity that campaigns for change, funds research to find a cure and supports people living with dementia today

### A unique opportunity







AON















**Alzheimer's Society** 

### Sources and estimates

Alzheimer's Society, Dementia 2014 report <a href="https://www.alzheimers.org.uk/sites/default/files/mig">https://www.alzheimers.org.uk/sites/default/files/mig</a> rate/downloads/dementia\_uk\_update.pdf

PHE, Dementia Intelligence Network <a href="https://digital.nhs.uk/data-and-information/national-indicator-library/dementia-65-estimated-diagnosis-rate">https://digital.nhs.uk/data-and-information/national-indicator-library/dementia-65-estimated-diagnosis-rate</a>

Primary papers from:
Carol Brayne, Fiona Matthews, and colleagues –
Cognitive Function in Ageing Studies (CFAS)

Martin Knapp, Carol Jagger and colleagues – Modelling Dementia (MODEM) study

Society

Against

### Thank you

James.pickett@alzheimers.org.uk@jamespickett12

alzheimers.org.uk/research




## Where are we with research into treatment of Alzheimer's disease?

Seth Love

University of Bristol

Current approaches




Cummings et al. Alzheimers Dement 2018; 4: 195-214


Problems with current approaches

- Amyloid cascade hypothesis?
- Earlier intervention?

- Amyloid cascade hypothesis?
- Earlier intervention?
- Multiple early amplifiers of disease
  - 。Tau
  - Inflammation
  - Hypoperfusion
- Multiple age-associated concurrent disease processes
  - Limbic TDP43 encephalopathy
  - Lewy body disease
  - Argyrophilic grain disease
  - Cerebrovascular disease

### In a cohort of people with AD





Robinson et al. Brain 2018; 141: 2181-93

Future research

- Better stratification
  - Better imaging
  - Better biomarkers
  - Polygenic risk profiling
- Combined interventions

#### **RISK REDUCTION**

- Don't smoke
- Keep a healthy weight
- Manage hypertension, depression, COPD, diabetes carefully
- Do regular exercise and plenty of social interaction...
- ...but don't drink alcohol excessively
- Personal risk assessment: <a href="https://anuadri.anu.edu.au/take-the-assessment.html">https://anuadri.anu.edu.au/take-the-assessment.html</a>
- Most risk factors are for Alzheimer's and Vascular Dementias

#### IDENTIFICATION

- Dementia is a <u>social</u> syndrome
- It is currently medicalised: diagnosis is by specialist or GP
- For diagnosis person needs to present to their GP and be willing to be diagnosed (stigma)
- Requires objective evidence of cognitive impairment plus functional impairment (cf MCI)
- There is no diagnostic test: tests are done mainly to exclude other diagnoses
- There are benefits but also potential harms from pursuing a diagnosis

#### **MANAGEMENT**

- Explanation
- Medication (treatment but also de-escalating other medication)
- Manage co-morbidities (which almost always co-exist), encourage self-care
- Advance planning
- Driving and DVLA (geographical context)
- Consider interpersonal relationships
- Encourage activation

### Questions?



**Dr James Pickett** 

Head of Research, Alzheimer's Society



**Prof Seth Love** 

Professor of
Neuropathology,
University of Bristol



**Dr Nick Cartmell** 

NHS General Practitioner; Primary Care Dementia Research Advisor, National Institute for Health Research



**Erik Pickett (Chair)** 

Longevity risk consultant
Club Vita



Join the discussion...

LinkedIn: Friends of Club Vita group; company/club-vita

Twitter: @ClubVita #dementia





### Thank you

This Powerpoint presentation contains confidential information belonging to Club VITA LLP (CV). CV are the owner or the licensee of all intellectual property rights in the Powerpoint presentation. All such rights are reserved. The material and charts included herewith are provided as background information for illustration purposes only. This Powerpoint presentation is not a definitive analysis of the subjects covered and should not be regarded as a substitute for specific advice in relation to the matters addressed. It is not advice and should not be relied upon. This Powerpoint presentation should not be released or otherwise disclosed to any third party without prior consent from CV. CV accept no liability for errors or omissions or reliance upon any statement or opinion herein.